CRSP — CRISPR Therapeutics AG
Is CRSP overbought or oversold? Here is the current MarketMoodz read.
CRISPR Therapeutics AG (CRSP) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $55.43. The rating moved from Oversold to Neutral on September 29, 2026.
- Public ratingNeutral (as of October 3, 2026)
- Last close$55.43
- Last changeMoved from Oversold to Neutral on September 29, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
CRISPR Therapeutics combines a validated CRISPR-Cas9 platform and a diversified pipeline with major partnerships that support meaningful long-term upside if clinical programs continue to produce positive data and reimbursement pathways prove viable. Near-term performance is likely to be driven by upcoming trial readouts, partnership milestones and financing dynamics; however, clinical setbacks, manufacturing scale issues, payer pricing pressure and competition create significant downside risk.
Key factors
- Proprietary CRISPR-Cas9 platform with demonstrated clinical proof-of-concept in ex vivo hematology programs and a high-profile commercial partnership that validates approach and de-risks early value creation.
- Diversified pipeline spanning ex vivo, in vivo and oncology programs, increasing the chance of one or more material value-driving readouts over the next 12–24 months.
- Large addressable markets for durable, potentially one-time genetic therapies (rare hematologic and genetic diseases), supporting attractive long-term revenue per patient assumptions if approved and reimbursed.
- Strategic partnerships and licensing (including established collaborators) provide non-dilutive funding, technical/clinical support and potential milestone revenue streams.
- Current market dislocation and risk-off tone can create near-term buying opportunities for fundamentally differentiated biotech assets with upcoming catalysts.
Risks
- Clinical development risk: unexpected safety signals, insufficient efficacy or delayed readouts in key trials could materially reduce valuation.
- Competition from other gene-editing and gene‑therapy companies (e.g., Intellia, Editas, Beam) that could capture priority for specific indications or develop superior delivery modalities.
- Regulatory and payer pressure including Medicare drug-price negotiation themes that could constrain pricing, access and reimbursement for high-cost, specialty gene therapies.
- Manufacturing and delivery challenges: scale-up, consistency, and cost of goods for gene-editing therapies can be complex and delay commercial rollouts.
- Funding and liquidity risk in a risk-off financing environment and an effectively closed healthcare IPO window, which could force dilution or slower program progression if non-dilutive capital is limited.
- Macro and geopolitical volatility that depresses biotech valuations and trading liquidity, increasing share-price volatility absent fresh company-specific catalysts.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for CRSP — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.